CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (249936) [Janelia Fluor® 669]
Novus Biologicals, part of Bio-Techne | Catalog # FAB1898JF669
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Western Blot
Label
Janelia Fluor 669
Antibody Source
Monoclonal Mouse IgG2A Clone # 249936
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human CD229/SLAMF3
Lys48-Lys454
Accession # Q9HBG7
Lys48-Lys454
Accession # Q9HBG7
Specificity
Detects human CD229/SLAMF3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross‑reactivity with recombinant mouse CD229 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD229/SLAMF3
Long Name
SLAM Family Member 3
Alternate Names
CD229, Ly9, SLAMF3
Gene Symbol
LY9
Additional CD229/SLAMF3 Products
Product Specific Notices
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...